Admission of Shares and Total Voting Rights

Oxford, UK - 19 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that further to the announcement made on 18 June 2024 regarding the subscription of shares by TSGH SAS, a subsidiary of Institut Mérieux SA in respect of a EUR 20 million (£16.9 million) investment, the Company confirms that 5,201,107 new Ordinary Shares of 50 pence each have been admitted today to the Premium segment of the Official List and to trading on the Main Market of the London Stock Exchange and the Company's issued share capital now consists of 105,268,630 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this announcement is 105,268,630.

The above figure 105,268,630 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.